ANIX - ITUS (Anixa Biosciences Inc.) ITUS

 ANIXのチャート


 ANIXの企業情報

symbol ANIx
会社名 Anixa Biosciences Inc (ITUS)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical Specialities  
業種 事業サポ―トサ―ビス   医療関連(Health Care)
概要 事業概要 アニーシャ・バイオサイエンス(Anixa Biosciences Inc.)(旧名: ITUS Corporation)腫瘍ベースの癌の早期発見用のCchekという診断プラットフォームの開発に従事する。Cchek癌検出プラットフォームは腫瘍の中および周囲に存在し、血流に入る特定の免疫細胞の存在、不存在および量を検出することによって、悪性腫瘍に対する患者の免疫応答を測定する。身体の免疫系とがん細胞を破壊する能力の変更・強化のかわりに、腫瘍発生時に血流に起こる微妙な免疫的変化を測定する技術とプロトコルを開発する。そのプロトコルを通じて、同社は生検で確認された癌患者の末梢血および健康患者の血液と癌患者の血液を区別するバイオマーカーを検出する。   ITUSは米国の特許技術開発・ライセンス企業。特許技術の開発、取得、ライセンス供与に従事する。同社の特許は、携帯電話やモバイル通信の暗号化、電子書籍用電気泳動ディスプレイ「ePaper」、インタ―ネット電話ゲ―トウェイ、ウェブ会議の暗号化、航空会社などによるロイヤルティ―プログラムのポイント転換システムなどを含む。本社はロサンゼルス。   
本社所在地 3150 Almaden Expressway Suite 250 San Jose CA 95118 USA
代表者氏名 Amit Kumar アミットクマール
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 310-484-5200
設立年月日 30256
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 7人
url https://www.anixa.com/
nasdaq_url https://www.nasdaq.com/symbol/anix
adr_tso
EBITDA EBITDA(百万ドル) -9.49194
終値(lastsale) 5.29
時価総額(marketcap) 98902612.34
時価総額 時価総額(百万ドル) 105.07230
売上高 売上高(百万ドル) 1.11250
企業価値(EV) 企業価値(EV)(百万ドル) 99.73120
当期純利益 当期純利益(百万ドル) -10.47935
決算概要 決算概要 BRIEF: For the nine months ended 31 July 2018 Anixa Biosciences Inc revenues increased from $363K to $1.1M. Net loss applicable to common stockholders increased 66% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in R&D increase from $213K to $2.7M (expense).

 ANIXのテクニカル分析


 ANIXのニュース

   Worldwide Industry for CAR-T Cell Therapy (2021 to 2027) - Players Profiled Include Aleta BioTherapeutics, Anixa Biosciences and BioNTech Among Others  2021/01/07 15:30:00 Benzinga
DUBLIN , Jan. 7, 2021 /PRNewswire/ -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials and Trends, 2021" report has been added to ResearchAndMarkets.com's offering. CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs." T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally.
   Anixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference  2021/01/05 13:30:00 PR Newswire
SAN JOSE, Calif., Jan. 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C….
   Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing  2020/12/14 14:00:00 PR Newswire
SAN JOSE, Calif., Dec. 14, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem GmbH have verified that one of their recently discovered…
   Analyzing The Price Action In Anixa Biosciences Stock Today  2020/12/10 10:24:00 Benzinga
Anixa Biosciences’s Stock Price And Volume Action Anixa Biosciences’s (NASDAQ: ANIX) stock has been rising Thursday, up 77.85% to a price of …
   Anixa Biosciences to Host Conference Call to Provide Update on Programs  2020/10/27 12:00:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m….
   Anixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference  2021/01/05 13:30:00 PR Newswire
SAN JOSE, Calif., Jan. 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C….
   Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing  2020/12/14 14:00:00 PR Newswire
SAN JOSE, Calif., Dec. 14, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem GmbH have verified that one of their recently discovered…
   Analyzing The Price Action In Anixa Biosciences Stock Today  2020/12/10 10:24:00 Benzinga
Anixa Biosciences’s Stock Price And Volume Action Anixa Biosciences’s (NASDAQ: ANIX) stock has been rising Thursday, up 77.85% to a price of …
   Anixa Biosciences to Host Conference Call to Provide Update on Programs  2020/10/27 12:00:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m….
   51 Biggest Movers From Yesterday  2020/10/02 08:57:27 Benzinga
Gainers Solid Biosciences Inc. (NASDAQ: SLDB ) shares climbed 70.4% to close at $3.46 on Thursday after the company announced the FDA has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. Enlivex Therapeutics Ltd. (NASDAQ: ENLV ) shares rose 48% to close at $8.79 after the company announced positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) surged 45.2% to close at $13.65 following a report suggesting Apollo's Covis said they are in talks to buy the company. American Equity Investment Life Holding Company (NYSE: AEL ) shares gained 44.1% to close at $31.68. American Equity yesterday named Graham Day to lead Eagle Life Insurance Company®, a subsidiary of American Equity. Gridsum Holding Inc. (NASDAQ: GSUM ) gained 39.7% to close at $1.69 after the company entered into definitive agreement for a going-private transaction. CBAK Energy Technology, Inc. (NASDAQ: CBAT ) climbed 25.7% to close at $2.54.
   Analyzing The Price Action In Anixa Biosciences Stock Today  2020/12/10 10:24:00 Benzinga
Anixa Biosciences’s Stock Price And Volume Action Anixa Biosciences’s (NASDAQ: ANIX) stock has been rising Thursday, up 77.85% to a price of …
   Anixa Biosciences to Host Conference Call to Provide Update on Programs  2020/10/27 12:00:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m….
   51 Biggest Movers From Yesterday  2020/10/02 08:57:27 Benzinga
Gainers Solid Biosciences Inc. (NASDAQ: SLDB ) shares climbed 70.4% to close at $3.46 on Thursday after the company announced the FDA has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. Enlivex Therapeutics Ltd. (NASDAQ: ENLV ) shares rose 48% to close at $8.79 after the company announced positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) surged 45.2% to close at $13.65 following a report suggesting Apollo's Covis said they are in talks to buy the company. American Equity Investment Life Holding Company (NYSE: AEL ) shares gained 44.1% to close at $31.68. American Equity yesterday named Graham Day to lead Eagle Life Insurance Company®, a subsidiary of American Equity. Gridsum Holding Inc. (NASDAQ: GSUM ) gained 39.7% to close at $1.69 after the company entered into definitive agreement for a going-private transaction. CBAK Energy Technology, Inc. (NASDAQ: CBAT ) climbed 25.7% to close at $2.54.
   Anixa Biosciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference  2020/09/08 12:00:00 PR Newswire
SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual 2020…
   Anixa nabs European patent covering CAR-T technology (NASDAQ:ANIX)  2020/07/10 11:33:43 Seeking Alpha
Thinly traded nano cap Anixa Biosciences (NASDAQ:ANIX) jumps 11% premarket on increased volume in reaction to its announcement that it has received an Inte

 関連キーワード  (事業サポ―トサ―ビス 米国株 ITUS ANIX Anixa Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)